ResMed (NYSE:RMD) intends to keep its CPAP masks that utilize magnets on the market despite a recall because it regards the action as a labeling correction rather than a product removal.

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

Goldman Sachs has initiated coverage on medical equipment maker ResMed and biotech giant CSL with a ‘buy’ ratings as analysts ...

In a report released today, Mathieu Chevrier from Citi maintained a Hold rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs ...

ResMed beats estimates on strong sleep apnea device sales January 24, 2024 ResMed said its respiratory masks containing magnets will remain on the market even though the U.S. Food and Drug ...